Last reviewed · How we verify

hepatitis A vaccine, DTaP, PCV10

KEMRI-Wellcome Trust Collaborative Research Program · FDA-approved active Biologic

hepatitis A vaccine, DTaP, PCV10 is a combination vaccine Biologic drug developed by KEMRI-Wellcome Trust Collaborative Research Program. It is currently FDA-approved for Prevention of hepatitis A, Prevention of diphtheria, Prevention of tetanus. Also known as: Synflorix.

This is a combination vaccine that stimulates the immune system to produce antibodies against hepatitis A virus, diphtheria, tetanus, pertussis, and pneumococcal pathogens.

This is a combination vaccine that stimulates the immune system to produce antibodies against hepatitis A virus, diphtheria, tetanus, pertussis, and pneumococcal pathogens. Used for Prevention of hepatitis A, Prevention of diphtheria, Prevention of tetanus.

At a glance

Generic namehepatitis A vaccine, DTaP, PCV10
Also known asSynflorix
SponsorKEMRI-Wellcome Trust Collaborative Research Program
Drug classcombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The vaccine contains inactivated hepatitis A virus antigen, toxoids for diphtheria and tetanus, acellular pertussis components, and pneumococcal polysaccharide conjugates. These antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these pathogens. Upon exposure to the actual pathogens, the primed immune system rapidly produces antibodies to neutralize or eliminate the infectious agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about hepatitis A vaccine, DTaP, PCV10

What is hepatitis A vaccine, DTaP, PCV10?

hepatitis A vaccine, DTaP, PCV10 is a combination vaccine drug developed by KEMRI-Wellcome Trust Collaborative Research Program, indicated for Prevention of hepatitis A, Prevention of diphtheria, Prevention of tetanus.

How does hepatitis A vaccine, DTaP, PCV10 work?

This is a combination vaccine that stimulates the immune system to produce antibodies against hepatitis A virus, diphtheria, tetanus, pertussis, and pneumococcal pathogens.

What is hepatitis A vaccine, DTaP, PCV10 used for?

hepatitis A vaccine, DTaP, PCV10 is indicated for Prevention of hepatitis A, Prevention of diphtheria, Prevention of tetanus, Prevention of pertussis (whooping cough), Prevention of pneumococcal disease (PCV10 serotypes).

Who makes hepatitis A vaccine, DTaP, PCV10?

hepatitis A vaccine, DTaP, PCV10 is developed and marketed by KEMRI-Wellcome Trust Collaborative Research Program (see full KEMRI-Wellcome Trust Collaborative Research Program pipeline at /company/kemri-wellcome-trust-collaborative-research-program).

Is hepatitis A vaccine, DTaP, PCV10 also known as anything else?

hepatitis A vaccine, DTaP, PCV10 is also known as Synflorix.

What drug class is hepatitis A vaccine, DTaP, PCV10 in?

hepatitis A vaccine, DTaP, PCV10 belongs to the combination vaccine class. See all combination vaccine drugs at /class/combination-vaccine.

What development phase is hepatitis A vaccine, DTaP, PCV10 in?

hepatitis A vaccine, DTaP, PCV10 is FDA-approved (marketed).

What are the side effects of hepatitis A vaccine, DTaP, PCV10?

Common side effects of hepatitis A vaccine, DTaP, PCV10 include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related